Lovastatin and gemfibrozil in the treatment of type 2a and type 2b hyperlipoproteinemia

Abstract

Subanalyses of previous multicenter studies comparing lovastatin and gemfibrozil were carried out to evaluate the merits of these agents in patients with different serum lipid phenotypes (type 2a and 2b hyperlipoproteinemia). Regardless of phenotype, lovastatin was more effective in lowering LDL-cholesterol, while gemfibrozil had a greater triglyceride… (More)
DOI: 10.1007/BF01409403

Topics

4 Figures and Tables